IN2014DN08011A - - Google Patents
Info
- Publication number
- IN2014DN08011A IN2014DN08011A IN8011DEN2014A IN2014DN08011A IN 2014DN08011 A IN2014DN08011 A IN 2014DN08011A IN 8011DEN2014 A IN8011DEN2014 A IN 8011DEN2014A IN 2014DN08011 A IN2014DN08011 A IN 2014DN08011A
- Authority
- IN
- India
- Prior art keywords
- mmp9
- functional fragment
- binding proteins
- gelatinase
- immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/027160 WO2013130078A1 (fr) | 2012-02-29 | 2012-02-29 | Anticorps dirigés contre la métalloprotéinase 9 de la matrice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08011A true IN2014DN08011A (fr) | 2015-05-01 |
Family
ID=45816000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8011DEN2014 IN2014DN08011A (fr) | 2012-02-29 | 2012-02-29 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9550836B2 (fr) |
| EP (1) | EP2820048B1 (fr) |
| JP (1) | JP6067756B2 (fr) |
| KR (1) | KR20140130724A (fr) |
| CN (1) | CN104395345A (fr) |
| AP (1) | AP2014007907A0 (fr) |
| AU (4) | AU2012318302C1 (fr) |
| BR (1) | BR112014021477A2 (fr) |
| CA (1) | CA2865530C (fr) |
| CL (1) | CL2014002282A1 (fr) |
| CO (1) | CO7061040A2 (fr) |
| CR (1) | CR20140443A (fr) |
| EA (1) | EA201491575A1 (fr) |
| EC (1) | ECSP14020504A (fr) |
| ES (1) | ES2731441T3 (fr) |
| HK (2) | HK1205153A1 (fr) |
| IN (1) | IN2014DN08011A (fr) |
| MD (1) | MD20140107A2 (fr) |
| MX (1) | MX2014010449A (fr) |
| PH (1) | PH12014501931A1 (fr) |
| SG (1) | SG11201405305PA (fr) |
| WO (1) | WO2013130078A1 (fr) |
| ZA (1) | ZA201406319B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201910348T4 (tr) | 2010-08-27 | 2019-08-21 | Gilead Biologics Inc | Matriks metalloproteinaz 9 için antikorlar. |
| MD20140107A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 din matrice |
| MD20140108A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 matriciale |
| SG11201606546VA (en) * | 2014-02-27 | 2016-09-29 | Gilead Sciences Inc | Antibodies to matrix metalloproteinase 9 and methods of use thereof |
| EP2985295A1 (fr) | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Anticorps spécifiques de MMP9 |
| EP2985296A1 (fr) | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Anticorps spécifiques de MMP9 |
| CN105037553B (zh) * | 2015-08-20 | 2018-04-17 | 内蒙古蒙元生物基因科技有限公司 | 一种能够检测癌症的免疫球蛋白 |
| JP2019513737A (ja) | 2016-04-08 | 2019-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法 |
| US10326830B1 (en) * | 2016-09-02 | 2019-06-18 | Amazon Technologies, Inc. | Multipath tunneling to a service offered at several datacenters |
| JP7141397B2 (ja) | 2016-12-16 | 2022-09-22 | ユニヴェルシテ・ドゥ・ボルドー | Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用 |
| US10941178B2 (en) | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
| JP7109440B2 (ja) | 2017-07-18 | 2022-07-29 | 第一三共株式会社 | 活性型ｍｍｐ－９結合ペプチド |
| CN110885375B (zh) * | 2019-12-20 | 2021-07-02 | 南京融捷康生物科技有限公司 | 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用 |
| CN111785321B (zh) * | 2020-06-12 | 2022-04-05 | 浙江工业大学 | 一种基于深度卷积神经网络的dna绑定残基预测方法 |
| CN117327186B (zh) * | 2023-07-12 | 2024-03-12 | 北京达成生物科技有限公司 | 结合mmp3蛋白的双特异性抗体及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| ATE435031T1 (de) * | 1999-07-13 | 2009-07-15 | Univ Southern California | Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine |
| CN1459505A (zh) * | 2002-05-21 | 2003-12-03 | 赵平 | 中国汉族人基质金属蛋白酶－9基因重构、表达、纯化及其医学应用 |
| JP4601426B2 (ja) * | 2002-09-06 | 2010-12-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体成分ｃ５に対する抗体を使用する喘息の処置の方法 |
| JP5808070B2 (ja) * | 2005-12-02 | 2015-11-10 | ジェネンテック， インコーポレイテッド | 結合ポリペプチド及びその使用 |
| PE20090765A1 (es) * | 2007-06-08 | 2009-07-10 | Irm Llc | Metodos y composiciones para inducir la apoptosis en celulas cancerosas |
| US8013125B2 (en) * | 2008-03-03 | 2011-09-06 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| CA2717576A1 (fr) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Proteines de liaison a la metalloproteinase 9 |
| US20110262396A1 (en) * | 2008-10-22 | 2011-10-27 | Dyax Corp. | Combination treatments comprising protease binding proteins for inflammatory disorders |
| WO2010059543A1 (fr) * | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Génération et caractérisation d’anticorps anti-notch pour utilisation thérapeutique et diagnostique |
| CA2787311C (fr) * | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Anticorps inhibant les metalloproteines |
| TR201910348T4 (tr) | 2010-08-27 | 2019-08-21 | Gilead Biologics Inc | Matriks metalloproteinaz 9 için antikorlar. |
| MD20140107A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 din matrice |
| MD20140108A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 matriciale |
-
2012
- 2012-02-29 MD MDA20140107A patent/MD20140107A2/ro not_active Application Discontinuation
- 2012-02-29 AP AP2014007907A patent/AP2014007907A0/xx unknown
- 2012-02-29 EA EA201491575A patent/EA201491575A1/ru unknown
- 2012-02-29 BR BR112014021477A patent/BR112014021477A2/pt not_active IP Right Cessation
- 2012-02-29 IN IN8011DEN2014 patent/IN2014DN08011A/en unknown
- 2012-02-29 KR KR1020147026786A patent/KR20140130724A/ko not_active Application Discontinuation
- 2012-02-29 MX MX2014010449A patent/MX2014010449A/es unknown
- 2012-02-29 CA CA2865530A patent/CA2865530C/fr not_active Expired - Fee Related
- 2012-02-29 US US14/382,301 patent/US9550836B2/en active Active
- 2012-02-29 WO PCT/US2012/027160 patent/WO2013130078A1/fr active Application Filing
- 2012-02-29 CN CN201280072749.6A patent/CN104395345A/zh active Pending
- 2012-02-29 EP EP12708473.9A patent/EP2820048B1/fr active Active
- 2012-02-29 ES ES12708473T patent/ES2731441T3/es active Active
- 2012-02-29 AU AU2012318302A patent/AU2012318302C1/en not_active Ceased
- 2012-02-29 SG SG11201405305PA patent/SG11201405305PA/en unknown
- 2012-02-29 JP JP2014559872A patent/JP6067756B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-27 ZA ZA2014/06319A patent/ZA201406319B/en unknown
- 2014-08-27 PH PH12014501931A patent/PH12014501931A1/en unknown
- 2014-08-28 CL CL2014002282A patent/CL2014002282A1/es unknown
- 2014-08-29 CO CO14190943A patent/CO7061040A2/es unknown
- 2014-09-24 CR CR20140443A patent/CR20140443A/es unknown
- 2014-09-26 EC ECIEPI201420504A patent/ECSP14020504A/es unknown
-
2015
- 2015-06-19 HK HK15105849.5A patent/HK1205153A1/xx unknown
- 2015-09-02 HK HK15108571.3A patent/HK1208036A1/xx unknown
- 2015-10-13 AU AU2015242967A patent/AU2015242967B2/en not_active Ceased
-
2016
- 2016-12-12 US US15/376,232 patent/US20170183421A1/en not_active Abandoned
-
2017
- 2017-08-16 AU AU2017216508A patent/AU2017216508B2/en not_active Ceased
- 2017-11-17 AU AU2017261626A patent/AU2017261626A1/en not_active Abandoned
-
2019
- 2019-01-10 US US16/245,169 patent/US10800857B2/en active Active
-
2020
- 2020-09-10 US US17/017,491 patent/US11634505B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
| IN2014DN08011A (fr) | ||
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| IN2014DN03451A (fr) | ||
| EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
| EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
| EA201792576A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| CL2010000521A1 (es) | Anticuerpo aislado o fragmento que bloquea la fijacion de la union de la proteina wise; secuencias de cdr de la cadena liviana y pesada; polipeptido inmunogenico de wise; composicion farmaceutica que comprende dicho anticuerpo. |